Willow Prescribing Data and Outcomes Signals: What the Evidence Actually Shows

What Is Willow and How Does Its Model Work?

Willow positions itself as a women-focused telehealth platform offering GLP-1 weight-loss medications alongside hormone therapies through a cash-pay, subscription-style model. The platform operates without insurance billing, which removes standard insurer utilization-management guardrails. Cash-pay GLP-1 telehealth grew sharply after 2021 as semaglutide and tirzepatide shortages pushed patients toward compounding pharmacies and direct-to-consumer prescribers.

The Cash-Pay GLP-1 Market Context

The FDA first approved semaglutide 2.4 mg (Wegovy) for chronic weight management in June 2021 based on the STEP-1 trial data. STEP-1 (N=1,961) showed 14.9% mean body weight reduction at 68 weeks versus 2.4% with placebo, P<0.001. That approval created sustained demand that brand supply could not immediately meet, opening a large market for cash-pay telehealth.

The FDA added semaglutide injection to its drug shortage database in 2022. The agency's shortage page is updated continuously and shows current availability status for all listed drugs. Semaglutide was removed from the shortage list in 2024. That removal means FDA-regulated 503B outsourcing facilities and 503A compounding pharmacies face new restrictions on producing compounded semaglutide, directly affecting platforms like Willow that may have relied on compounded supply.

How Willow Differs From Insurance-Based Care

Insurance-based GLP-1 prescribing requires prior authorization that typically mandates documented BMI criteria, comorbidity confirmation, and often a supervised diet program. Cash-pay platforms skip that step. Faster access has genuine value for patients who qualify clinically but face prior-auth delays. The risk is that the same friction removal can lead to prescribing outside guideline criteria.

The American Association of Clinical Endocrinology 2023 clinical practice guideline specifies GLP-1 agonist initiation for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Patients should confirm their prescribing clinician is applying those criteria.

Does Willow Have Published Outcomes Data?

No. As of January 2025, Willow has not published a peer-reviewed outcomes dataset, a preprint, or an independently audited cohort analysis covering its patient population. This is not unique to Willow. Most direct-to-consumer telehealth brands in the GLP-1 space have not published outcomes data. The absence of data is itself a signal worth weighing.

What Outcomes Data From GLP-1 Trials Actually Show

Because Willow-specific data does not exist, the only valid reference points are the FDA-approved trials and real-world registry studies.

STEP-1 remains the foundational semaglutide weight-loss trial. At 68 weeks, 86.4% of participants on semaglutide 2.4 mg achieved ≥5% weight loss, compared with 31.5% on placebo. Gastrointestinal adverse events occurred in 74.2% of the semaglutide group versus 47.9% placebo.

For tirzepatide, SURMOUNT-1 (N=2,539) showed mean weight reduction of 20.9% at 72 weeks with the 15 mg dose. The SURMOUNT-1 primary results were published in the New England Journal of Medicine in 2022. These trial figures apply to FDA-approved formulations, not compounded versions.

The Compounding Gap

Compounded semaglutide is not bioequivalent-tested against Ozempic or Wegovy. The FDA has stated explicitly that compounded drugs are not FDA-approved and have not been shown to be safe and effective. Any platform prescribing compounded semaglutide after the shortage-list removal should be able to explain its legal basis for doing so. Patients should ask directly.

Regulatory and Licensing Red Flags to Check

Willow's regulatory standing is the single most verifiable aspect of any cash-pay telehealth platform. Checking it takes under 15 minutes and costs nothing.

State Medical Board Verification

Every prescribing clinician must hold an active, unrestricted medical license in the patient's state. State medical board license lookups are available through the Federation of State Medical Boards DocInfo database. A license that shows probation, restriction, or prior disciplinary action is a hard stop.

Telehealth prescribing across state lines requires the prescriber to hold a license in the patient's state, not only in the state where the clinician practices. Many telehealth platforms use multistate compact licenses. The Interstate Medical Licensure Compact allows expedited licensure in member states, and current member states are listed on the IMLC website.

LegitScript and Pharmacy Verification

LegitScript is an independent certification body used by Google, Meta, and major payment processors to verify online pharmacy and telehealth compliance. LegitScript's database of certified and rogue internet pharmacies is publicly searchable. As of January 2025, patients should conduct that lookup directly, as certification status changes.

Any pharmacy dispensing prescription GLP-1 medications must hold a current NABP (National Association of Boards of Pharmacy) license in the dispensing state. NABP's Drug Outlet Database allows consumers to verify pharmacy accreditation. Compounding pharmacies should also hold 503A or 503B registration with the FDA.

BBB Complaints and Patterns

The Better Business Bureau collects consumer complaints and assigns ratings based on complaint volume, response patterns, and resolution. BBB profiles are publicly searchable at bbb.org. Patterns worth noting include repeated billing disputes, difficulty canceling subscriptions, and complaints about medications not arriving. These patterns appear across multiple cash-pay GLP-1 telehealth brands and are not specific to Willow, but any platform's BBB record should be reviewed before payment information is entered.

What Patients Actually Report: Complaint Themes

Because no peer-reviewed complaint dataset exists for Willow specifically, the relevant comparison is the documented complaint pattern for cash-pay GLP-1 telehealth platforms broadly.

Billing and Subscription Disputes

The Federal Trade Commission's ongoing scrutiny of negative-option subscription billing applies directly to telehealth models that charge a monthly fee before a prescription is confirmed. The FTC's enforcement of the Negative Option Rule has intensified since 2022. Patients should read cancellation terms before entering payment details.

Medication Authenticity Concerns

Compounded semaglutide sold through telehealth has generated FDA warnings. In May 2024, the FDA warned consumers about reports of adverse events associated with compounded semaglutide products, including incorrect dosing. Products labeled as "semaglutide" that contain semaglutide sodium or semaglutide acetate rather than the base compound are not equivalent to FDA-approved formulations.

Access to Prescribers After Enrollment

A documented complaint pattern across multiple cash-pay telehealth platforms involves difficulty reaching a prescribing clinician after the initial consultation. The Ryan Haight Online Pharmacy Consumer Protection Act requires a valid patient-prescriber relationship before controlled substances can be prescribed online. The DEA's telehealth prescribing rules were updated in 2023 following pandemic-era flexibilities. GLP-1 agonists are not controlled substances, so the Act does not apply directly, but the spirit of requiring a genuine clinical relationship still governs standard-of-care expectations.

A Clinical Verification Framework for Willow (and Any GLP-1 Telehealth Platform)

The table below summarizes the minimum verification steps a patient should complete before starting any cash-pay GLP-1 program. These steps apply to Willow and to every competitor in the same space.

| Verification Step | Where to Check | Pass Criteria | |---|---|---| | Prescriber license | FSMB DocInfo | Active, unrestricted, licensed in patient's state | | Pharmacy NABP status | NABP Drug Outlet Database | Current accreditation, no disciplinary action | | LegitScript certification | LegitScript.com lookup | Certified status, not "rogue" or "not recommended" | | Compounded drug legal basis | Ask platform directly | Written explanation citing FDA 503A/503B registration | | BBB record | BBB.org | Review complaint patterns, not just star rating | | Subscription cancellation terms | Platform Terms of Service | Clear cancellation process, no auto-renewal traps | | Clinical eligibility criteria | Platform intake form | BMI ≥30 or BMI ≥27 plus documented comorbidity |

How GLP-1 Outcomes Should Be Measured in a Telehealth Setting

Even if Willow collected outcomes data internally, the metrics matter. Weight loss percentage at 12, 24, and 52 weeks is the minimum clinically meaningful endpoint. The SCALE Obesity and Prediabetes trial (liraglutide 3.0 mg, N=3,731) showed 8.0% mean weight loss at 56 weeks versus 2.6% placebo. That trial was published in the New England Journal of Medicine in 2015 and remains a benchmark for 56-week GLP-1 outcomes.

Dropout and Adherence Data

Dropout rate is as important as weight loss at endpoint. In STEP-1, 7.3% of semaglutide participants discontinued due to adverse events versus 3.1% on placebo. A platform with no dropout data is a platform with no accountability for tolerability management. Patients should ask any telehealth provider what percentage of patients are still active at 6 months and 12 months.

Cardiovascular and Metabolic Co-Endpoints

SELECT (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo in adults with overweight or obesity and established cardiovascular disease. SELECT results were published in the New England Journal of Medicine in 2023. A telehealth platform that presents weight loss alone as the value proposition is omitting the most clinically significant benefit the drug class has demonstrated.

Women-Specific Considerations

Willow's women-focused branding implies familiarity with female-specific pharmacology. Menstrual cycle irregularities, PCOS-related insulin resistance, and perimenopause metabolic changes all affect GLP-1 response. The Endocrine Society's 2023 clinical practice guideline on obesity management notes that hormonal fluctuations affect adiposity and should be addressed alongside GLP-1 therapy. A platform claiming women-specific expertise should document how it screens and adjusts for these variables.

What "Willow Legit?" Actually Means Clinically

The consumer question "Is Willow legit?" conflates at least four separate questions: Is it legally operating? Are its prescribers licensed? Are its drugs authentic? Does its clinical model meet standard-of-care? Each question has a different answer pathway.

Legal Operation

A company can be legally incorporated and operating a website while still dispensing medications through an unlicensed pharmacy or prescribing outside guideline criteria. Legal business registration and clinical legitimacy are not the same thing.

Prescriber Credentials

The most direct test of clinical legitimacy is the prescribing clinician's license status. The FSMB Physician Data Center provides disciplinary history and license verification for U.S. Physicians. Patients should request the prescribing clinician's full name and NPI number before any prescription is issued.

Drug Authenticity

FDA-approved Wegovy (semaglutide 2.4 mg) and Ozempic (semaglutide 0.5/1/2 mg) come with NDC numbers and manufacturer lot traceability. FDA's National Drug Code Directory is publicly searchable. Compounded products do not appear in that database by definition. A patient receiving compounded semaglutide through Willow or any other platform cannot independently verify potency or sterility through the NDC system.

Standard-of-Care Alignment

The Obesity Medicine Association's 2023 clinical practice statement recommends that GLP-1 prescribing occur within a comprehensive obesity treatment program that includes behavioral counseling. Platforms that offer medication without any behavioral support component are departing from that standard. Patients should ask whether their subscription includes clinician access for dose titration and adverse event management, not just an initial consultation.

Practical Steps Before Starting Willow or Any Similar Platform

Ask the platform for the prescribing clinician's full name, NPI, and state license number before paying. Run that NPI through CMS's NPI Registry and the license through FSMB. Ask which pharmacy will dispense the medication and run that pharmacy through NABP's database. Request written confirmation of whether the medication is FDA-approved brand or compounded, and if compounded, ask for the 503A or 503B registration number of the compounding pharmacy.

The FDA's BeSafeRx campaign provides a consumer checklist for verifying online pharmacy safety. Print it and use it for any cash-pay telehealth platform.

A patient who meets AACE criteria (BMI ≥30, or BMI ≥27 with hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea) and cannot access insurance-covered GLP-1 therapy has a legitimate medical need that cash-pay telehealth can address. The verification steps above take less time than a pharmacy visit and can prevent receiving a counterfeit or subpotent product.